<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00930488</url>
  </required_header>
  <id_info>
    <org_study_id>12803</org_study_id>
    <secondary_id>TOPAS</secondary_id>
    <secondary_id>AX 0601</secondary_id>
    <secondary_id>12867 - AX0601AT</secondary_id>
    <secondary_id>12868 - AX0601PK</secondary_id>
    <secondary_id>12869 - AX0601EG</secondary_id>
    <secondary_id>12870 - AX0601NL</secondary_id>
    <secondary_id>12973 - AX0601SK</secondary_id>
    <secondary_id>12974 - AX0601SG</secondary_id>
    <secondary_id>13026 - AX0601ID</secondary_id>
    <secondary_id>13046 - AX0601PH</secondary_id>
    <secondary_id>13111 - AX0601RO</secondary_id>
    <secondary_id>13065 - AX0601CN</secondary_id>
    <secondary_id>13207 - AX0601FR</secondary_id>
    <secondary_id>13166 - AX0601MY</secondary_id>
    <nct_id>NCT00930488</nct_id>
  </id_info>
  <brief_title>Treatment of Patients With Acute Sinusitis</brief_title>
  <official_title>Treatment of Patients With Acute Sinusitis in Daily Practice</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      For each patient, an initial visit and at least one follow-up visit at the end of treatment
      should be documented by the treating physician in the case report form.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of potential benefits of an antibacterial therapy with Avelox® (moxifloxacin) in patients with acute bacterial sinusitis to whom this treatment was prescribed. Especially the time to improvement and resolution of clinical signs and symptoms of</measure>
    <time_frame>Documentation at baseline and at at least one follow-up visit. Evaluation of therapy outcome at last follow-up visit at end of therapy (approximately after 7 days).</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of tolerability and safety of Avalox® in daily practice were investigated.</measure>
    <time_frame>Evaluation of therapy outcome at last follow-up visit at end of therapy (approximately after 7 days).</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient characteristics in acute bacterial sinusitis</measure>
    <time_frame>Documentation at baseline visit.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>History and frequency of sinusitis episodes</measure>
    <time_frame>Documentation at baseline visit.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diagnostic procedures and therapeutic options chosen by physicians in daily practice</measure>
    <time_frame>Documentation at baseline visit.</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">6777</enrollment>
  <condition>Acute Bacterial Sinusitis</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Avelox (Moxifloxacin, BAY12-8039)</intervention_name>
    <description>Patients with a diagnosis of acute bacterial sinusitis who take moxifloxacin</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <biospec_retention>None Retained</biospec_retention>
  <biospec_descr>
    <textblock>
      n.a.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with a diagnosis of acute bacterial sinusitis who take moxifloxacin
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Any patient with a diagnosis of acute bacterial sinusitis treated with Avelox® - in
             accordance with the local production information.

        Exclusion Criteria:

          -  Those specified in the local product information - contraindications and precautions
             must be considered.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Bahrain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Jordan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Kuwait</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Lebanon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Pakistan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>United Arab Emirates</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Yemen</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Bahrain</country>
    <country>China</country>
    <country>Egypt</country>
    <country>France</country>
    <country>Germany</country>
    <country>Indonesia</country>
    <country>Jordan</country>
    <country>Kuwait</country>
    <country>Lebanon</country>
    <country>Malaysia</country>
    <country>Netherlands</country>
    <country>Pakistan</country>
    <country>Philippines</country>
    <country>Romania</country>
    <country>Saudi Arabia</country>
    <country>Singapore</country>
    <country>United Arab Emirates</country>
    <country>Yemen</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 29, 2009</study_first_submitted>
  <study_first_submitted_qc>June 29, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 30, 2009</study_first_posted>
  <last_update_submitted>November 19, 2012</last_update_submitted>
  <last_update_submitted_qc>November 19, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 20, 2012</last_update_posted>
  <responsible_party>
    <name_title>Global Medical Affairs Therapeutic Area Head</name_title>
    <organization>Bayer HealthCare AG</organization>
  </responsible_party>
  <keyword>Moxifloxacin</keyword>
  <keyword>MXF</keyword>
  <keyword>Avelox</keyword>
  <keyword>Sinusitis</keyword>
  <keyword>Acute bacterial sinusitis, ABS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sinusitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Fluoroquinolones</mesh_term>
    <mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

